alpha-En (ALPE) 10-Q 14 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 14, 2019
Document And Entity Information
Entity Registrant Name	alpha-En Corp
Entity Central Index Key	0001023298
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		38,879,799
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets
Cash	$ 278	$ 518
Grant receivable	35
Restricted cash		15
Prepaid expenses	71
Total current assets	384	533
Long-term restricted cash	35	35
Property and equipment, net	597	632
Right-of-use assets	825
Total assets	1,841	1,200
Current liabilities
Accounts payable and accrued expenses	807	557
Advances from related parties	36	36
Current portion of deferred rent		10
Current portion of operating lease liability	127
Total current liabilities	970	603
Deferred rent		105
Noncurrent operating lease liability	806
Total liabilities	1,776	708
COMMITMENTS AND CONTINGENCIES
Stockholders' deficit:
Common stock value	394	390
Additional paid-in capital	23,719	21,586
Treasury stock at cost: 714,750 shares as of September 30, 2019 and December 31, 2018	(69)	(69)
Accumulated deficit	(29,421)	(25,623)
Total stockholders' deficit	(5,377)	(3,716)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT AND TEMPORARY EQUITY	1,841	1,200
Series A Preferred Stock [Member]
Current liabilities
Preferred Stock value	4,532	4,208
Series B Preferred Stock [Member]
Current liabilities
Preferred Stock value	910
Class B Common Stock [Member]
Stockholders' deficit:
Common stock value

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Common stock, par or stated value per share	$ 0.01	$ 0.01
Common stock, shares authorized	57,000,000	57,000,000
Common stock, shares, issued	39,444,549	39,044,549
Common stock, shares, outstanding	38,729,799	38,329,799
Treasury stock, shares	714,750	714,750
Series A Preferred [Member]
Preferred stock, par or stated value per share	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	4,532	4,208
Preferred stock, shares outstanding	4,532	4,208
Preferred stock, liquidation preference	$ 4,532	$ 4,208
Series B Preferred Stock [Member]
Preferred stock, par or stated value per share	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	910
Preferred stock, shares outstanding	910
Preferred stock, liquidation preference	$ 910
Class B Common Stock [Member]
Common stock, par or stated value per share
Common stock, shares authorized	1,000,000	1,000,000
Common stock, shares, issued
Common stock, shares, outstanding

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues
Total revenues	$ 58		$ 58
Operating expenses
General and administrative	1,076	1,213	3,220	3,396
Legal and professional fees	60	103	229	364
Research and development (includes stock based compensation of $18 and $59 for the three and nine months ended September 30, 2019 and $(28) and $(245) for the three and nine months ended September 30, 2018, respectively. See Note 7)	101	372	399	837
Total operating expenses	1,237	1,688	3,848	4,597
Other income (loss)
Other expenses	(3)	(2)	(9)	(2)
Interest income		1	1	1
Total other income (loss)	(3)	(1)	(8)	(1)
Net loss	(1,182)	(1,689)	(3,798)	(4,598)
Less: net loss attributable to non-controlling interest				(155)
Net loss attributable to controlling interest	(1,182)	(1,689)	(3,798)	(4,443)
Net loss attributable to alpha-En Corporation common stockholders	$ (1,239)	$ (1,789)	$ (4,807)	$ (6,361)
Net loss per share attributable to alpha-En Corporation common stockholders
Basic and diluted	$ (0.03)	$ (0.05)	$ (0.12)	$ (0.18)
Weighted average shares outstanding:
Basic and diluted	39,444,549	35,890,676	39,278,981	35,693,698
Series A Preferred Stock [Member]
Other income (loss)
Less: Dividends accrued on Preferred Stock	$ (111)	$ (100)	$ (324)	$ (275)
Less: Deemed dividend on Preferred Stock				(687)
Less: Deemed dividend - beneficial conversion feature on Preferred Stock				(956)
Series B Preferred Stock [Member]
Other income (loss)
Less: Dividends accrued on Preferred Stock	(20)		(40)
Less: Deemed dividend on Preferred Stock	22		(192)
Less: Deemed dividend - beneficial conversion feature on Preferred Stock	52		(453)
Grant [Member]
Revenues
Total revenues	$ 58		$ 58

Condensed Statements of Opera_2

Condensed Statements of Operations (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Research and Development Expense [Member]
Stock based compensation	$ 18	$ 59	$ (28)	$ (245)

Condensed Statement of Stockhol

Condensed Statement of Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2017	$ 334	$ 18,482	$ (69)	$ (20,276)	$ (704)	$ (2,233)
Balance, shares at Dec. 31, 2017	33,350,506		714,750
Stock based compensation		(81)				(81)
Options exercised for cash		2				2
Options exercised for cash, shares	10,000
Issuance of warrants to purchase common stock associated with preferred stock offering		687				687
Deemed dividend on Series A preferred stock		(687)				(687)
Beneficial conversion feature of Series A preferred stock		956				956
Deemed dividends related to beneficial conversion feature of Series A preferred stock		(956)				(956)
Accrued Series A Preferred Stock dividends		(77)				(77)
Net loss				(632)	(29)	(661)
Balance at Mar. 31, 2018	$ 334	18,326	$ (69)	(20,908)	(733)	(3,050)
Balance, shares at Mar. 31, 2018	33,360,506		714,750
Balance at Dec. 31, 2017	$ 334	18,482	$ (69)	(20,276)	(704)	(2,233)
Balance, shares at Dec. 31, 2017	33,350,506		714,750
Accrued Series B Preferred Stock dividends
Net loss						(4,598)
Balance at Sep. 30, 2018	$ 390	21,301	$ (69)	(24,719)		(3,097)
Balance, shares at Sep. 30, 2018	39,044,589		714,750
Balance at Mar. 31, 2018	$ 334	18,326	$ (69)	(20,908)	(733)	(3,050)
Balance, shares at Mar. 31, 2018	33,360,506		714,750
Stock based compensation		1,173				1,173
Issuance of warrants to purchase common stock associated with preferred stock offering		687				687
Deemed dividend on Series A preferred stock		(687)				(687)
Beneficial conversion feature of Series A preferred stock		956				956
Deemed dividends related to beneficial conversion feature of Series A preferred stock		(956)				(956)
Accrued Series A Preferred Stock dividends		(98)				(98)
Shares issued for acquiring ownership of subsidiary	$ 30	(889)			859
Shares issued for acquiring ownership of subsidiary, shares	3,018,190
Issuance of common stock for cash in a private placement	$ 9	991				1,000
Issuance of common stock for cash in a private placement, shares	867,768
Series A Preferred Stock converted to common stock		55				55
Series A Preferred Stock converted to common stock, Shares	31,460
Warrants exercised for cash	$ 10	190				200
Warrants exercised for cash, Shares	1,000,000
Net loss				(2,122)	(126)	(2,248)
Balance at Jun. 30, 2018	$ 383	19,748	$ (69)	(23,030)		(2,968)
Balance, shares at Jun. 30, 2018	38,277,924		714,750
Stock based compensation		840				840
Options exercised for cash	$ 1	19				20
Options exercised for cash, shares	100,000
Accrued Series A Preferred Stock dividends		(100)				(100)
Issuance of common stock for cash in a private placement	$ 6	794				800
Issuance of common stock for cash in a private placement, shares	666,665
Net loss				(1,689)		(1,689)
Balance at Sep. 30, 2018	$ 390	21,301	$ (69)	(24,719)		(3,097)
Balance, shares at Sep. 30, 2018	39,044,589		714,750
Balance at Dec. 31, 2018	$ 390	21,586	$ (69)	(25,623)		(3,716)
Balance, shares at Dec. 31, 2018	39,044,549		714,750
Stock based compensation		710				710
Accrued Series A Preferred Stock dividends		(105)				(105)
Net loss				(1,214)		(1,214)
Balance at Mar. 31, 2019	$ 390	22,191	$ (69)	(26,837)		(4,325)
Balance, shares at Mar. 31, 2019	39,044,549		714,750
Balance at Dec. 31, 2018	$ 390	21,586	$ (69)	(25,623)		(3,716)
Balance, shares at Dec. 31, 2018	39,044,549		714,750
Accrued Series B Preferred Stock dividends						(40)
Net loss						(3,798)
Balance at Sep. 30, 2019	$ 394	23,719	$ (69)	(29,421)		(5,377)
Balance, shares at Sep. 30, 2019	39,444,549		714,750
Balance at Mar. 31, 2019	$ 390	22,191	$ (69)	(26,837)		(4,325)
Balance, shares at Mar. 31, 2019	39,044,549		714,750
Stock based compensation		944				944
Issuance of warrants to purchase common stock associated with preferred stock offering		214				214
Accrued Series A Preferred Stock dividends		(108)				(108)
Deemed dividend on Series B preferred stock		(214)				(214)
Beneficial conversion feature of Series B preferred stock		505				505
Deemed dividends related to beneficial conversion feature of Series B preferred stock		(505)				(505)
Accrued Series B Preferred Stock dividends		(20)				(20)
Net loss				(1,402)		(1,402)
Balance at Jun. 30, 2019	$ 390	23,007	$ (69)	(28,239)		(4,911)
Balance, shares at Jun. 30, 2019	39,044,549		714,750
Stock based compensation		747				747
Issuance of warrants to purchase common stock associated with preferred stock offering		(22)				(22)
Accrued Series A Preferred Stock dividends		(111)				(111)
Issuance of common stock for cash in a private placement	$ 4	96				100
Issuance of common stock for cash in a private placement, shares	400,000
Deemed dividend on Series B preferred stock		22				22
Beneficial conversion feature of Series B preferred stock		(52)				(52)
Deemed dividends related to beneficial conversion feature of Series B preferred stock		52				52
Accrued Series B Preferred Stock dividends		(20)				(20)
Net loss				(1,182)		(1,182)
Balance at Sep. 30, 2019	$ 394	$ 23,719	$ (69)	$ (29,421)		$ (5,377)
Balance, shares at Sep. 30, 2019	39,444,549		714,750

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities
Net loss	$ (3,798)	$ (4,598)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	91	83
Stock-based compensation	2,401	1,932
Amortization of right-of-use assets	78
Changes in operating assets and liabilities of business, net of acquisitions:
Grant receivable	(35)
Prepaid expenses	(71)
Deferred rent		118
Operating lease liability	(85)
Accounts payable and accrued expenses	250	(553)
Net cash used in operating activities	(1,169)	(3,018)
Cash flows from investing activities
Purchase of fixed assets	(56)	(180)
Net cash used in investing activities	(56)	(180)
Cash flows from financing activities
Proceeds from issuance of preferred stock and warrants	820	1,700
Proceeds from issuance of common stock in private placements	100	1,800
Options exercised for cash		22
Warrants exercised for cash		200
Advances from related parties	50
Repayments of advances from related parties		(22)
Net cash provided by financing activities	970	3,700
Net (decrease) increase in cash	(255)	502
Cash and restricted cash at beginning of period	568	612
Cash and restricted cash at end of period	313	1,114
Non cash financing and investing activities:
Beneficial conversion feature of Series A Preferred Stock and deemed dividends related to beneficial conversion feature of Series A Preferred Stock		(956)
Beneficial conversion feature of Series B Preferred Stock and deemed dividends related to beneficial conversion feature of Series B Preferred Stock	(453)
Issuance of warrants in Preferred Stock offering and deemed dividend on Series A Preferred Stock		(687)
Issuance of warrants in Preferred Stock offering and deemed dividend on Series B Preferred Stock	(192)
Accrued Series A Preferred Stock dividends	(324)	(275)
Accrued Series B Preferred Stock dividends	(40)
Conversion of advances from related parties to preferred stock	50	250
Series A Preferred Stock converted to common stock		55
Purchase of assets included in accounts payable		67
Forgiveness of the lease payments		$ 104

Organization and Operations

Organization and Operations	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Operations	Note 1 - Organization and Operations alpha-En Corporation (the “Company”) was incorporated in Delaware on March 7, 1997. Since 2008, the focus of the Company’s business has been developing new technologies for manufacturing highly pure lithium metal, a raw material for use in lightweight, high energy density batteries, in an environmentally friendly manner for commercial purposes. In 2013, the Company invented a new process for the production of highly pure lithium metal and associated products at room temperature. The Company subsequently broadened its focus to develop products and processes derived from the Company’s new core proprietary technology, including battery components and compounds of lithium.

Going Concern and Liquidity

Going Concern and Liquidity	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Liquidity	Note 2 - Going Concern and Liquidity The Company’s condensed financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. As reflected in the condensed financial statements, the Company had an accumulated deficit of approximately $29.4 million at September 30, 2019, a net loss of approximately $3.8 million and approximately $1.2 million net cash used in operating activities for the nine months ended September 30, 2019. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company is attempting to further develop the intellectual property associated with its technology; broaden its patent portfolio; scale up its production of various products; and begin generating revenue; however, the Company’s cash position is not sufficient to support its daily operations for the foreseeable future. The ability of the Company to continue as a going concern is dependent upon its ability to raise additional funds by way of a public or private offering and its ability to further develop its technology and generate sufficient revenue. While the Company believes in the viability of its technology and in its ability to raise additional funds by way of a public or private offering, there can be no assurances to that effect. The condensed financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Significant and Critical Accoun

Significant and Critical Accounting Policies and Practices	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Significant and Critical Accounting Policies and Practices	Note 3 - Significant and Critical Accounting Policies and Practices Correction of Prior Quarter Error The Company recorded an immaterial adjustment during the three months ended September 30, 2019, to properly record the cancellation of 100 shares of its issued Series B preferred stock and the resulting issuance 400,000 shares of common stock during the three months ended June 30, 2019. Due to the immaterial nature of this adjustment, there was no impact on basic or diluted earnings per share and net loss. The Company evaluated this correction considering both quantitative and qualitative factors and concluded it was immaterial to previously issued condensed financial statements. Basis of Presentation and Principles of Consolidation The condensed balance sheet at December 31, 2018 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. The unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments (consisting of normal recurring adjustments unless otherwise indicated) which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Certain information in footnote disclosures normally included in the financial statements prepared in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the SEC rules and regulations for interim reporting. The financial results for the periods presented may not be indicative of the full year’s results. These unaudited condensed financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the fiscal year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K filed on April 1, 2019. Use of Estimates The Company’s condensed financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value used in estimating the value of warrants, stock-based compensation, accrued expenses and provisions for income taxes. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. Restricted Cash The following is a summary of cash and restricted cash total as presented in the statements of cash flows for as of September 30, 2019 and 2018 (dollars are in thousands): As of September 30, 2019 2018 Cash $ 278 $ 1,064 Restricted cash - 15 Long-term restricted cash 35 35 Total cash and restricted cash $ 313 $ 1,114 Grant Income We have concluded that the Company’s government grants are not within the scope of ASC Topic 606 as they do not meet the definition of a contract with a customer. The Company concluded that the grants meet the definition of a contribution and are non-reciprocal transactions, and have also concluded that Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition does not apply, as the Company is a business entity and the grants are with governmental agencies. In the absence of applicable guidance under US GAAP, the Company developed a policy for the recognition of grant revenue when the conditions of the grant are met. Leases Effective January 1, 2019, the Company accounts for its leases under ASC 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. In calculating the right of use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term. The Company continues to account for leases in the prior period financial statements under ASC Topic 840. Other than above, there have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 1, 2019. Loss Per Share Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share excludes the potential impact of common stock options, convertible preferred stock and outstanding common stock purchase warrants because their effect would be anti-dilutive. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at September 30, 2019 and 2018 are as follows: As of September 30, 2019 2018 Warrants to purchase common stock 5,667,292 4,719,292 Options to purchase common stock 19,129,000 16,024,000 Preferred stock convertible into common stock 4,412,304 2,348,060 Total 29,208,596 23,091,352 Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standard Updates (“ASUs”). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on our balance sheets or statements of operations. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. For public companies, ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 (including interim periods within those periods) using a modified retrospective approach and early adoption is permitted. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a) the existence of a lease, (b) lease classification or (c) determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous U.S. GAAP. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. The Company adopted Topic 842 on January 1, 2019, using the optional transition method to apply the new guidance as of January 1, 2019, rather than as of the earliest period presented, and elected the package of practical expedients described above. Based on the analysis, on January 1, 2019, the Company recorded right of use assets of approximately $903,000, lease liability of approximately $1.0 million and eliminated deferred rent of approximately $115,000 (See Note 8). In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 4 - Property and Equipment The components of property and equipment as of September 30, 2019 and December 31, 2018, at cost are (dollars in thousands): Useful Life (Years) September 30, 2019 December 31, 2018 Lab equipment 7 $ 471 $ 415 Office furniture and equipment 3 31 31 Leasehold improvement 7 379 379 Gross property and equipment 881 825 Less: Accumulated depreciation and amortization (284 ) (193 ) Property and equipment, net $ 597 $ 632 The Company’s depreciation and amortization expense for the three months ended September 30, 2019 and 2018, was $29,000 and $32,000, respectively. The Company’s depreciation and amortization expense for the nine months ended September 30, 2019 and 2018, was $91,000 and $83,000, respectively.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Note 5 - Related Party Transactions Advances from Stockholders From time to time, stockholders of the Company advances funds to the Company for working capital purposes. Those advances are unsecured, non-interest bearing and due on demand. During the nine months ended September 30, 2019, the Company borrowed $50,000 from Steven M. Payne and subsequently the Company converted this advance into Series B Preferred Stock. As of September 30, 2019 and December 31, 2018, the outstanding amounts of the advances from related parties was approximately $36,000.

Temporary Equity

Temporary Equity	9 Months Ended
	Sep. 30, 2019
Temporary Equity [Abstract]
Temporary Equity	Note 6 - Temporary Equity Series A Preferred Stock The following table summarizes the Company’s Series A Preferred Stock activities for the six months ended June 30, 2019 (dollars in thousands): Series A Preferred Stock Shares Amount Total Series A temporary equity as of December 31, 2018 4,208 $ 4,208 Accrued Series A Preferred Stock dividends 213 213 Total Series A temporary equity as of June 30, 2019 4,421 $ 4,421 As of June 30, 2019, the Company has 4,421 shares of Series A Preferred Stock convertible into 2,528,812 shares of common stock, and the dividends accrued and outstanding were $701,000 and reflected in carrying value of temporary equity. Series B Preferred Stock On April 16, 2019 the Company entered into a preferred stock purchase agreement (“Stock Purchase Agreement”) with several accredited and institutional investors (including certain executives and members of the Company’s Board of Directors), pursuant to which the Company agreed to issue and sell in a private placement up to 1,500 shares of its newly designated Series B Preferred Stock, par value $0.01 per share, as well as warrants to purchase the Company’s common stock, at a purchase price of $1,000 per unit, for total gross proceeds of up to $1.5 million. The Company has raised $970,000 from the issuance of 970 shares of Series B Preferred Stock and 970,000 warrants to purchase the Company’s common stock through June 30, 2019, including $50,000 advances from related parties converted into Series B Preferred Stock. Each share of Series B preferred stock is convertible in 2,000 shares of common stock and is redeemable by the Company at any time after the first anniversary. Upon liquidation of the Company, each share of Series B is entitled to receive a distribution of assets before any distribution to holders of common stock, and after satisfaction of all liabilities, in an amount equal to the original issuance price plus any accrued but unpaid dividends. The Series B preferred stock is entitled to cumulative non-compounding dividends at an annual rate of 10%, which are to be paid quarterly. At the Company’s election the dividend may be paid in either stock or cash. On the issuance date, the Company estimated the fair value of the warrants at $357,000 using the Black-Scholes option pricing model using the following primary assumptions: contractual term of 5.0 years, volatility rate of 71.9%, risk-free interest rate of 2.40% and expected dividend rate of 0%. Based on the warrant’s relative fair value to the fair value of the Series B Preferred Stock, approximately $214,000 of the $357,000 of aggregate fair value was allocated to the warrants, creating a corresponding preferred stock discount in the same amount. Due to the reduction of allocated proceeds to Series B Preferred Stock, the effective conversion price was approximately $0.39 per share creating a beneficial conversion feature of $505,000 which reduced the carrying value of the Series B Preferred Stock. Since the conversion option of the Series B Preferred Stock was immediately exercisable, the beneficial conversion feature was immediately accreted to preferred dividends, resulting in an increase in the carrying value of the Series B Preferred Stock. On April 8, 2019, in connection with the sale and issuance of the Series B Preferred Stock, the Company filed with the Secretary of State of the State of Delaware a certificate of designation establishing and designating the Series B Preferred Stock and the rights, preferences, privileges and limitations thereof. The following table summarizes the Company’s Series B Preferred Stock activities for the six months ended June 30, 2019 (dollars in thousands): Series B Preferred Stock Shares Amount Total Series B temporary equity as of December 31, 2018 - $ - Sale of Series B Preferred Stock 920 920 Conversion of advances into preferred stock 50 50 Beneficial conversion feature of Series B Preferred Stock - (505 ) Deemed dividends related to beneficial conversion feature of Series B Preferred Stock - 505 Accrued Series B Preferred Stock dividends 20 20 Deemed dividend on Series B Preferred Stock - 214 Fair Value of common stock warrant issued with Series B Preferred Stock - (214 ) Total Series B temporary equity as of June 30, 2019 990 $ 990 As of June 30, 2019, the Company has 990 shares of Series B Preferred Stock convertible into 1,980,000 shares of common stock, and the dividends accrued and outstanding were $20,000 and reflected in carrying value of temporary equity.

Stockholders' (Deficit) Equity

Stockholders' (Deficit) Equity	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Stockholders' (Deficit) Equity	Note 7 - Stockholders’ (Deficit) Equity Common Stock On April 23, 2019, the Company entered into a private placement offering with an investor and issued 400,000 shares of its common stock for $100,000. On August 13, 2019 the Board of Directors of the Company and a subset of the Company’s stockholders representing in excess of a majority of the Company’s currently issued and outstanding voting stock approved of the amendment and restatement of the Company’s Certificate of Incorporation (the “Restated Certificate”) to increase the authorized capital stock of the Company to 85,000,000 shares, consisting of 82,000,000 shares of common stock, par value one cent ($0.01) per share, 1,000,000 shares of Class B common stock, par value one cent ($0.01) per share, and 2,000,000 shares of preferred stock, par value one cent ($0.01) per share. Pursuant to applicable law, the Restated Certificate will become effective twenty days after the distribution of an information statement to all of the Company’s stockholders and after the filing of the Restated Certificate with the Delaware Secretary of State. Stock Options The Company uses the Black-Scholes model to value stock options which requires certain assumptions. The fair value of the Company’s common stock was based upon the publicly quoted price on the date that the final approval of the awards was obtained. The Company does not expect to pay dividends in the foreseeable future so therefore the expected dividend yield is 0%. The expected term for stock options granted with service conditions represents the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the approach prescribed by the Securities and Exchange Commission’s Staff Accounting Bulletin for “plain vanilla” options. The expected term for stock options granted with performance and/or market conditions represents the period estimated by management by which the performance conditions will be met. The Company obtained the risk-free interest rate from publicly available data published by the Federal Reserve. The Company uses a methodology in estimating its volatility percentage from a computation that was based on a comparison of average volatility rates of similar companies to a computation based on the standard deviation of the Company’s own underlying stock price’s daily logarithmic returns. The grant date fair value of stock options granted during the nine months ended September 30, 2019 and 2018 was $818,000 and $8.4 million, respectively. On August 13, 2019, the Board approved the increase of the number of shares available under the 2016 Equity Plan to 30,000,000. The fair value of options granted during the nine months ended September 30, 2019 and 2018 were estimated using the following weighted-average assumptions: For the Nine Months Ended 2019 2018 Exercise price $ 0.26 $ 2.05 Expected stock price volatility 65 % 78 % Risk-free rate of interest 2.23 % 2.68 % Term (years) 3.1 4.0 A summary of option activity for employees and nonemployees under the Company’s stock option plan for the nine months ended September 30, 2019 is presented below: Number of Shares Weighted Average Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2018 15,724,000 $ 1.60 $ 1,924,000 4.5 Granted 7,070,000 0.26 2,000,000 4.6 Cancelled (1,750,000 ) 1.90 - - Expired (1,915,000 ) 0.55 604,000 - Outstanding as of September 30, 2019 19,129,000 $ 1.18 $ 2,518,000 4.4 Options vested and expected to vest as of September 30, 2019 19,129,000 $ 1.18 $ 2,518,000 4.4 Options vested and exercisable as of September 30, 2019 6,751,500 $ 0.97 $ 1,018,000 3.0 Estimated future stock-based compensation expense relating to unvested stock options is approximately $6.0 million as of September 30, 2019 and will be amortized over 3.0 years. Warrants A summary of the status of the Company’s outstanding warrants as of September 30, 2019 and changes during the nine months then ended is presented below: Number of Warrants Weighted Average Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2018 4,797,292 $ 1.62 $ 340,000 3.1 Issued 870,000 0.75 - 4.5 Outstanding as of September 30, 2019 5,667,292 $ 1.49 $ 134,000 2.8 Warrants exercisable as of September 30, 2019 5,417,292 $ 1.50 $ 134,000 2.7 Stock-based Compensation Expense For the three months ended September 30, 2019, there were approximately $729,000 and $18,000 stock-based compensation expenses included in the general and administrative and research and development expense, respectively, compared to $868,000 and $(28,000) for the three months ended September 30, 2018, respectively. For the nine months ended September 30, 2019, there were approximately $2.3 million and $59,000 stock-based compensation expenses included in the general and administrative and research and development expense, respectively, compared to stock-based compensation expenses of $2.2 million and $(245,000) for the nine months ended September 30, 2018, respectively.

Leases

Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Leases	Note 8 - Leases The Company leases office and laboratory space located in Yonkers, New York for its operations, resulting in an operating lease right-of-use asset, a current portion of operating lease liability, and a noncurrent operating lease liability on the balance sheet. Operating lease costs are recorded on a straight-line basis within operating expenses. The Company’s total lease expense is comprised of the following (dollars in thousands): For the Three For the Nine Operating leases Operating lease cost $ 51 $ 152 Total rent expense $ 51 $ 152 Additional information regarding the Company’s leasing activities as a lessee is as follows (dollars in thousands): For the Three For the Nine Operating cash flows from operating leases $ 53 $ 159 Remaining lease term – operating leases 5.5 5.5 Weighted-average discount rate – operating leases 10.0 % 10.0 % As of September 30, 2019, contractual minimal lease payments are as follows (in thousands): 2019 $ 53 2020 215 2021 219 2022 222 2023 225 2024 229 2025 58 Total 1,221 Less present value discount (288 ) Less current portion of operating lease liability (127 ) Non-current operating lease liability $ 806

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 9 - Subsequent Events On August 13, 2019 the Board of Directors of the Company and a subset of the Company’s stockholders representing in excess of a majority of the Company’s currently issued and outstanding voting stock approved of the amendment and restatement of the Company’s Certificate of Incorporation (the “Restated Certificate”) to increase the authorized capital stock of the Company to 85,000,000 shares, consisting of 82,000,000 shares of common stock, par value one cent ($0.01) per share, 1,000,000 shares of Class B common stock, par value one cent ($0.01) per share, and 2,000,000 shares of preferred stock, par value one cent ($0.01) per share, the Board of Directors and stockholders also approved of an increase in the number of shares available for grant under the Company’s 2016 Omnibus Equity Plan to 30,000,000 shares. Pursuant to applicable law, the Restated Certificate will become effective twenty days after the distribution of an information statement to all of the Company’s stockholders and after the filing of the Restated Certificate with the Delaware Secretary of State. The Company filed a preliminary information statement on Schedule 14C with the Securities and Exchange commission on November 11, 2019 related to the Restated Certificate.

Significant and Critical Acco_2

Significant and Critical Accounting Policies and Practices (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Correction of Prior Quarter Error	Correction of Prior Quarter Error The Company recorded an immaterial adjustment during the three months ended September 30, 2019, to properly record the cancellation of 100 shares of its issued Series B preferred stock and the resulting issuance 400,000 shares of common stock during the three months ended June 30, 2019. Due to the immaterial nature of this adjustment, there was no impact on basic or diluted earnings per share and net loss. The Company evaluated this correction considering both quantitative and qualitative factors and concluded it was immaterial to previously issued condensed financial statements.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The condensed balance sheet at December 31, 2018 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. The unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments (consisting of normal recurring adjustments unless otherwise indicated) which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Certain information in footnote disclosures normally included in the financial statements prepared in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the SEC rules and regulations for interim reporting. The financial results for the periods presented may not be indicative of the full year’s results. These unaudited condensed financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the fiscal year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K filed on April 1, 2019.
Use of Estimates	Use of Estimates The Company’s condensed financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value used in estimating the value of warrants, stock-based compensation, accrued expenses and provisions for income taxes. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.
Restricted Cash	Restricted Cash The following is a summary of cash and restricted cash total as presented in the statements of cash flows for as of September 30, 2019 and 2018 (dollars are in thousands): As of September 30, 2019 2018 Cash $ 278 $ 1,064 Restricted cash - 15 Long-term restricted cash 35 35 Total cash and restricted cash $ 313 $ 1,114
Grant Income	Grant Income We have concluded that the Company’s government grants are not within the scope of ASC Topic 606 as they do not meet the definition of a contract with a customer. The Company concluded that the grants meet the definition of a contribution and are non-reciprocal transactions, and have also concluded that Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition does not apply, as the Company is a business entity and the grants are with governmental agencies. In the absence of applicable guidance under US GAAP, the Company developed a policy for the recognition of grant revenue when the conditions of the grant are met.
Leases	Leases Effective January 1, 2019, the Company accounts for its leases under ASC 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. In calculating the right of use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term. The Company continues to account for leases in the prior period financial statements under ASC Topic 840. Other than above, there have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 1, 2019.
Loss Per Share	Loss Per Share Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share excludes the potential impact of common stock options, convertible preferred stock and outstanding common stock purchase warrants because their effect would be anti-dilutive. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at September 30, 2019 and 2018 are as follows: As of September 30, 2019 2018 Warrants to purchase common stock 5,667,292 4,719,292 Options to purchase common stock 19,129,000 16,024,000 Preferred stock convertible into common stock 4,412,304 2,348,060 Total 29,208,596 23,091,352
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standard Updates (“ASUs”). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on our balance sheets or statements of operations. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. For public companies, ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 (including interim periods within those periods) using a modified retrospective approach and early adoption is permitted. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a) the existence of a lease, (b) lease classification or (c) determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous U.S. GAAP. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. The Company adopted Topic 842 on January 1, 2019, using the optional transition method to apply the new guidance as of January 1, 2019, rather than as of the earliest period presented, and elected the package of practical expedients described above. Based on the analysis, on January 1, 2019, the Company recorded right of use assets of approximately $903,000, lease liability of approximately $1.0 million and eliminated deferred rent of approximately $115,000 (See Note 8). In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting

Significant and Critical Acco_3

Significant and Critical Accounting Policies and Practices (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Cash and Restricted Cash	The following is a summary of cash and restricted cash total as presented in the statements of cash flows for as of September 30, 2019 and 2018 (dollars are in thousands): As of September 30, 2019 2018 Cash $ 278 $ 1,064 Restricted cash - 15 Long-term restricted cash 35 35 Total cash and restricted cash $ 313 $ 1,114
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at September 30, 2019 and 2018 are as follows: As of September 30, 2019 2018 Warrants to purchase common stock 5,667,292 4,719,292 Options to purchase common stock 19,129,000 16,024,000 Preferred stock convertible into common stock 4,412,304 2,348,060 Total 29,208,596 23,091,352

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	The components of property and equipment as of September 30, 2019 and December 31, 2018, at cost are (dollars in thousands): Useful Life (Years) September 30, 2019 December 31, 2018 Lab equipment 7 $ 471 $ 415 Office furniture and equipment 3 31 31 Leasehold improvement 7 379 379 Gross property and equipment 881 825 Less: Accumulated depreciation and amortization (284 ) (193 ) Property and equipment, net $ 597 $ 632

Temporary Equity (Tables)

Temporary Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Series A Preferred Stock [Member]
Schedule of Temporary Equity	The following table summarizes the Company’s Series A Preferred Stock activities for the nine months ended September 30, 2019 (dollars in thousands): Series A Preferred Stock Shares Amount Total Series A temporary equity as of December 31, 2018 4,208 $ 4,208 Accrued Series A Preferred Stock dividends 324 324 Total Series A temporary equity as of September 30, 2019 4,532 $ 4,532
Series B Preferred Stock [Member]
Schedule of Temporary Equity	The following table summarizes the Company’s Series B Preferred Stock activities for the nine months ended September 30, 2019 (dollars in thousands): Series B Preferred Stock Shares Amount Total Series B temporary equity as of December 31, 2018 - $ - Sale of Series B Preferred Stock 820 820 Conversion of advances into preferred stock 50 50 Beneficial conversion feature of Series B Preferred Stock - (453 ) Deemed dividends related to beneficial conversion feature of Series B Preferred Stock - 453 Accrued Series B Preferred Stock dividends 40 40 Deemed dividend on Series B Preferred Stock - 192 Fair Value of common stock warrant issued with Series B Preferred Stock - (192 ) Total Series B temporary equity as of September 30, 2019 910 $ 910

Stockholders' (Deficit) Equity

Stockholders' (Deficit) Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Schedule of Fair Value of Assumptions	The fair value of options granted during the nine months ended September 30, 2019 and 2018 were estimated using the following weighted-average assumptions: For the Nine Months Ended 2019 2018 Exercise price $ 0.26 $ 2.05 Expected stock price volatility 65 % 78 % Risk-free rate of interest 2.23 % 2.68 % Term (years) 3.1 4.0
Schedule of Stock Options, Activity	A summary of option activity for employees and nonemployees under the Company’s stock option plan for the nine months ended September 30, 2019 is presented below: Number of Shares Weighted Average Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2018 15,724,000 $ 1.60 $ 1,924,000 4.5 Granted 7,070,000 0.26 2,000,000 4.6 Cancelled (1,750,000 ) 1.90 - - Expired (1,915,000 ) 0.55 604,000 - Outstanding as of September 30, 2019 19,129,000 $ 1.18 $ 2,518,000 4.4 Options vested and expected to vest as of September 30, 2019 19,129,000 $ 1.18 $ 2,518,000 4.4 Options vested and exercisable as of September 30, 2019 6,751,500 $ 0.97 $ 1,018,000 3.0
Schedule of Outstanding Warrants	A summary of the status of the Company’s outstanding warrants as of September 30, 2019 and changes during the nine months then ended is presented below: Number of Warrants Weighted Average Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2018 4,797,292 $ 1.62 $ 340,000 3.1 Issued 870,000 0.75 - 4.5 Outstanding as of September 30, 2019 5,667,292 $ 1.49 $ 134,000 2.8 Warrants exercisable as of September 30, 2019 5,417,292 $ 1.50 $ 134,000 2.7

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Schedule of Operating Lease Expenses	The Company’s total lease expense is comprised of the following (dollars in thousands): For the Three For the Nine Operating leases Operating lease cost $ 51 $ 152 Total rent expense $ 51 $ 152
Schedule of Lessee Leasing Activity	Additional information regarding the Company’s leasing activities as a lessee is as follows (dollars in thousands): For the Three For the Nine Operating cash flows from operating leases $ 53 $ 159 Remaining lease term – operating leases 5.5 5.5 Weighted-average discount rate – operating leases 10.0 % 10.0 %
Summary of Contractual Minimal Lease Payments	As of September 30, 2019, contractual minimal lease payments are as follows (in thousands): 2019 $ 53 2020 215 2021 219 2022 222 2023 225 2024 229 2025 58 Total 1,221 Less present value discount (288 ) Less current portion of operating lease liability (127 ) Non-current operating lease liability $ 806

Going Concern and Liquidity (De

Going Concern and Liquidity (Details Narrative) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (29,421)						$ (29,421)		$ (25,623)
Net loss	$ (1,182)	$ (1,402)	$ (1,214)	$ (1,689)	$ (2,248)	$ (661)	(3,798)	$ (4,598)
Net cash used in operating activities							$ (1,169)	$ (3,018)

Significant and Critical Acco_4

Significant and Critical Accounting Policies and Practices (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Jan. 02, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Right of use assets	$ 825	$ 825
ASU 2016-02 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Right of use assets			$ 903
Lease liability			1,000
Eliminated deferred rent			$ 115
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Adjustment to record number of shares cancelled	100
Number of share issued for common stock	400,000	1,820,000

Significant and Critical Acco_5

Significant and Critical Accounting Policies and Practices - Summary of Cash and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018
Accounting Policies [Abstract]
Cash	$ 278	$ 518	$ 1,064
Restricted cash		15	15
Long-term restricted cash	35	$ 35	35
Total cash and restricted cash	$ 313		$ 1,114

Significant and Critical Acco_6

Significant and Critical Accounting Policies and Practices - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Franchisor Disclosure [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	29,208,596	23,091,352
Warrants to Purchase Common Stock [Member]
Franchisor Disclosure [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	5,667,292	4,719,292
Options to Purchase Common Stock [Member]
Franchisor Disclosure [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	19,129,000	16,024,000
Preferred Stock Convertible into Common Stock [Member]
Franchisor Disclosure [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	4,412,304	2,348,060

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 29	$ 32	$ 91	$ 83

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 881	$ 825
Less: Accumulated depreciation and amortization	(284)	(193)
Property and equipment, net	$ 597	632
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Gross property and equipment	$ 471	415
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Gross property and equipment	$ 31	31
Leasehold Improvement [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Gross property and equipment	$ 379	$ 379

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Advances from related parties	$ 36	$ 36
Steven M. Payne [Member]
Related Party Transaction [Line Items]
Borrowed from stockholders	$ 50

Temporary Equity (Details Narra

Temporary Equity (Details Narrative) $ / shares in Units, $ in Thousands	Apr. 16, 2019USD ($)$ / sharesshares	Sep. 30, 2019$ / sharesshares	Sep. 30, 2018shares	Jun. 30, 2018shares	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Aug. 13, 2019$ / shares	Dec. 31, 2018$ / shares
Common stock, par or stated value per share | $ / shares		$ 0.01			$ 0.01			$ 0.01
Gross proceeds					$ 100	$ 1,800
Advances from related parties					$ 50
Estimated the fair value of the warrants	$ 192
Common Stock [Member]
Number of share issued for common stock | shares		400,000	666,665	867,768
Common stock, par or stated value per share | $ / shares							$ 0.01
Private Placement [Member]
Gross proceeds	$ 1,500
Private Placement [Member] | Board of Directors [Member] | Common Stock [Member]
Sale of stock, price per share | $ / shares	$ 1,000
Series A Preferred Stock [Member]
Share convertible into number of common stock | shares		4,532			4,532
Number of share issued for common stock | shares					2,592,304
Dividend accrued and outstanding					$ 812
Series B Preferred Stock [Member]
Share convertible into number of common stock | shares	2,000	910			910
Number of share issued for common stock | shares		400,000			1,820,000
Dividend accrued and outstanding					$ 40
Cummulative non-compounding dividends annual rate	10.00%
Estimated the fair value of the warrants	$ 321
Warrant term	5 years
Conversion price per share | $ / shares					$ 0.39
Beneficial conversion feature					$ 453
Series B Preferred Stock [Member] | Volatility Rate [Member]
Warrants and rights outstanding, measurement input	0.719
Series B Preferred Stock [Member] | Risk-Free Interest Rate [Member]
Warrants and rights outstanding, measurement input	0.0240
Series B Preferred Stock [Member] | Expected Dividend Rate [Member]
Warrants and rights outstanding, measurement input	0
Series B Preferred Stock [Member] | Board of Directors [Member]
Sale of stock, number of shares issued | shares	970
Gross proceeds	$ 870
Warrants to purchase shares of common stock | shares	870,000
Advances from related parties	$ 50
Series B Preferred Stock [Member] | Private Placement [Member] | Board of Directors [Member]
Sale of stock, number of shares issued | shares	1,500
Common stock, par or stated value per share | $ / shares	$ 0.01

Temporary Equity - Schedule of

Temporary Equity - Schedule of Temporary Equity (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019
Accrued Preferred Stock dividends	$ (111)	$ (108)	$ (105)	$ (100)	$ (98)	$ (77)
Beneficial conversion feature of Series B Preferred Stock	(52)	505
Deemed dividends related to beneficial conversion feature of Series B Preferred Stock	52	(505)
Deemed dividend on Series B Preferred Stock	$ 22	$ (214)
Series A Preferred Stock [Member]
Total temporary equity, shares beginning			4,208				4,208
Total temporary equity, beginning			$ 4,208				$ 4,208
Accrued Preferred Stock dividends, shares							324
Accrued Preferred Stock dividends							$ 324
Total temporary equity, shares ending	4,532						4,532
Total temporary equity, ending	$ 4,532						$ 4,532
Series B Preferred Stock [Member]
Total temporary equity, shares beginning
Total temporary equity, beginning
Accrued Preferred Stock dividends, shares							40
Accrued Preferred Stock dividends							$ 40
Sale of Series B Preferred Stock, shares							820
Sale of Series B Preferred Stock							$ 820
Conversion of advances into preferred stock, shares							50
Conversion of advances into preferred stock							$ 50
Beneficial conversion feature of Series B Preferred Stock, shares
Beneficial conversion feature of Series B Preferred Stock							$ (453)
Deemed dividends related to beneficial conversion feature of Series B Preferred Stock, shares
Deemed dividends related to beneficial conversion feature of Series B Preferred Stock							$ 453
Deemed dividend on Series B Preferred Stock, shares
Deemed dividend on Series B Preferred Stock							$ 192
Fair Value of common stock warrant issued with Series B Preferred Stock, shares
Fair Value of common stock warrant issued with Series B Preferred Stock							$ (192)
Total temporary equity, shares ending	910						910
Total temporary equity, ending	$ 910						$ 910

Stockholders' (Deficit) Equit_2

Stockholders' (Deficit) Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Apr. 23, 2019	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Aug. 13, 2019	Dec. 31, 2018
Number of shares issued for common stock		$ 100	$ 800	$ 1,000
Capital stock shares authorized							85,000,000
Common stock, par or stated value per share		$ 0.01			$ 0.01			$ 0.01
Stock-based compensation expense					$ 2,401	$ 1,932
General and Administrative Expense [Member]
Stock-based compensation expense		$ 729	868		2,300	2,200
Research and Development Expense [Member]
Stock-based compensation expense		$ 18	$ (28)		$ 59	(245)
Class B Common Stock [Member]
Capital stock shares authorized							1,000,000
Common stock, par or stated value per share							$ 0.01
Common Stock [Member]
Number of share issued for common stock		400,000	666,665	867,768
Number of shares issued for common stock		$ 4	$ 6	$ 9
Capital stock shares authorized							82,000,000
Common stock, par or stated value per share							$ 0.01
Preferred Stock [Member]
Capital stock shares authorized							2,000,000
Preferred stock, par or stated value per share							$ 0.01
Stock Options [Member]
Expected dividend yield					0.00%
Fair value of stock option granted					$ 818	$ 8,400
Stock based compensation expense relating to unvested		$ 6,000			$ 6,000
Amortized period					3 years
Stock Options [Member] | 2016 Equity Plan [Member]
Increase of the number of shares available		30,000,000			30,000,000
Investor [Member]
Number of share issued for common stock	400,000
Number of shares issued for common stock	$ 100

Stockholders' (Deficit) Equit_3

Stockholders' (Deficit) Equity - Schedule of Fair Value of Assumptions (Details) - $ / shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Equity [Abstract]
Exercise price	$ 0.26	$ 2.05
Expected stock price volatility	65.00%	78.00%
Risk-free rate of interest	2.23%	2.68%
Term (years)	3 years 1 month 6 days	4 years

Stockholders' (Deficit) Equit_4

Stockholders' (Deficit) Equity - Schedule of Stock Options, Activity (Details) - Employees and Nonemployees [Member] $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Number of Shares, Outstanding, Beginning Balance | shares	15,724,000
Number of Shares, Outstanding, Granted | shares	7,070,000
Number of Shares, Outstanding, Cancelled | shares	(1,750,000)
Number of Shares, Options Expired | shares	(1,915,000)
Number of Shares, Outstanding, Ending Balance | shares	19,129,000
Number of Shares, Options vested and expected to vest | shares	19,129,000
Number of Shares, Options vested and exercisable | shares	6,751,500
Weighted Average Exercise Price, Outstanding, Beginning Balance | $ / shares	$ 1.60
Weighted Average Exercise Price, Outstanding, Granted | $ / shares	0.26
Weighted Average Exercise Price, Outstanding, Cancelled | $ / shares	1.90
Weighted Average Exercise Price, Options Expired | $ / shares	0.55
Weighted Average Exercise Price, Outstanding, Ending Balance | $ / shares	1.18
Weighted Average Exercise Price, Options vested and expected to vest | $ / shares	1.18
Weighted Average Exercise Price, Options vested and exercisable | $ / shares	$ 0.97
Intrinsic Value, Outstanding, Beginning Balance | $	$ 1,924
Intrinsic Value, Outstanding, Granted | $	2,000
Intrinsic Value, Outstanding, Cancelled | $
Intrinsic Value, Options Expired | $	604
Intrinsic Value, Outstanding, Ending Balance | $	2,518
Intrinsic Value, Options vested and expected to vest | $	2,518
Intrinsic Value, Options vested and exercisable | $	$ 1,018
Weighted Average Remaining Contractual Life (in years), Outstanding, Beginning Balance	4 years 6 months
Weighted Average Remaining Contractual Life (in years), Outstanding, Granted	4 years 7 months 6 days
Weighted Average Remaining Contractual Life (in years), Outstanding, Cancelled	0 years
Weighted Average Remaining Contractual Life (in years), Options Expired	0 years
Weighted Average Remaining Contractual Life (in years), Outstanding, Ending Balance	4 years 4 months 24 days
Weighted Average Remaining Contractual Life (in years), Options vested and expected to vest	4 years 4 months 24 days
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable	3 years

Stockholders' (Deficit) Equit_5

Stockholders' (Deficit) Equity - Schedule of Outstanding Warrants (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Equity [Abstract]
Number of Shares, Warrants Outstanding Beginning | shares	4,797,292
Number of Shares, Warrants Issued | shares	870,000
Number of Shares, Warrants Outstanding Ending | shares	5,667,292
Number of Shares, Warrants Exercisable Ending | shares	5,417,292
Weighted Average Exercise Price Per Share Warrants Outstanding Beginning | $ / shares	$ 1.62
Weighted Average Exercise Price Per Share Warrants Issued | $ / shares	0.75
Weighted Average Exercise Price Per Share Warrants Outstanding Ending | $ / shares	1.49
Weighted Average Exercise Price Per Share Exercisable | $ / shares	$ 1.50
Aggregate Intrinsic Value Outstanding Beginning | $	$ 340
Aggregate Intrinsic Value Outstanding Ending | $	134
Aggregate Intrinsic Value Exercisable | $	$ 134
Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning	3 years 1 month 6 days
Weighted Average Remaining Contractual Life Warrants Outstanding, Issued	4 years 6 months
Weighted Average Remaining Contractual Life Warrants Outstanding Ending	2 years 9 months 18 days
Weighted Average Remaining Contractual Life Warrants Exercisable	2 years 8 months 12 days

Leases - Schedule of Operating

Leases - Schedule of Operating Lease Expenses (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Leases [Abstract]
Operating lease cost	$ 51	$ 152
Total rent expense	$ 51	$ 152

Leases - Schedule of Lessee Lea

Leases - Schedule of Lessee Leasing Activity (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2019USD ($)
Leases [Abstract]
Operating cash flows from operating leases	$ 53	$ 159
Remaining lease term - operating leases	5 years 6 months	5 years 6 months
Weighted-average discount rate - operating leases	10.00%	10.00%

Leases - Summary of Contractual

Leases - Summary of Contractual Minimal Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Leases [Abstract]
2019	$ 53
2020	215
2021	219
2022	222
2023	225
2024	229
2025	58
Total	1,221
Less present value discount	(288)
Less current portion of operating lease liability	(127)
Non-current operating lease liability	$ 806

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - $ / shares	Nov. 13, 2019	Sep. 30, 2019	Aug. 13, 2019	Dec. 31, 2018
Capital stock, authorized			85,000,000
Common stock, par or stated value per share		$ 0.01		$ 0.01
Board of Directors and Stockholders [Member] | 2016 Omnibus Equity Plan [Member] | Maximum [Member]
Number of shares available for grant			30,000,000
Sam Pitroda [Member] | Subsequent Event [Member]
Number of options exercisable	1,500,000
Sam Pitroda [Member] | Subsequent Event [Member] | First Anniversary [Member]
Number of options exercisable	500,000
Sam Pitroda [Member] | Subsequent Event [Member] | Second Anniversary [Member]
Number of options exercisable	500,000
Sam Pitroda [Member] | Subsequent Event [Member] | Third Anniversary [Member]
Number of options exercisable	500,000
Class B Common Stock [Member]
Capital stock, authorized			1,000,000
Common stock, par or stated value per share			$ 0.01
Common Stock [Member]
Capital stock, authorized			82,000,000
Common stock, par or stated value per share			$ 0.01
Preferred Stock [Member]
Capital stock, authorized			2,000,000
Preferred stock, par or stated value per share			$ 0.01
Option One [Member] | Sam Pitroda [Member] | Subsequent Event [Member]
Options to purchase common stock	7,000,000
Options exercise price	$ 2.08
Option Two [Member] | Sam Pitroda [Member] | Subsequent Event [Member]
Options to purchase common stock	3,000,000
Options exercise price	$ 0.54